Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
David L KendlerH G BoneF MassariE GielenS PalaciosJ MaddoxC YanS YueR V DinavahiC LibanatiA GrauerPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2019)
After 12 months off-treatment, a second romosozumab course again led to rapid and large BMD gains. Following denosumab, BMD gains with romosozumab were smaller than with initial treatment. No new safety findings were observed during the second course.